Industries > Pharma > Dermatological Drugs Market Forecast 2020-2030

Dermatological Drugs Market Forecast 2020-2030

Psoriasis, Skin Infection, Acne, Dermatitis, Others

PUBLISHED: 31 October 2019
PAGES: 355
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
SKU: PHA0577 Categories: , Tags: , , ,

The revenue of the dermatological drugs market in 2018 is estimated at $31bn and is expected to grow at a CAGR of 3.7% in the first half of the forecast period. Psoriasis drugs segment accounted for the largest share of the market in 2018, this segment accounted for 38% of the global dermatological drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 355-page report you will receive 133 tables and 154 figures– all unavailable elsewhere.

The 355-page report provides clear detailed insight into the dermatological drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Dermatological drugs market forecasts from 2020-2030

• This report also breaks down the revenue forecast for the main submarkets:
• Psoriasis
• Skin Infections
• Acne
• Dermatitis

• Analysis of the Psoriasis drugs market. Revenue forecasts to 2030 are provided for the following drugs:
• Humira
• Stelara
• Enbrel
• Remicade
• Taltz
• Otezla
• Cosentyx

• Analysis of the Skin Infections drugs market. Revenue forecasts to 2030 are provided for the following drugs:
• Cubicin
• Zyvox
• Valtrex
• Canesten
• Lamisil
• Bactroban

Dermatological Drugs Market Forecast 2020-2030

• Analysis of the Acne drugs market. Revenue forecasts to 2030 are provided for the following drugs:
• Solodyn
• Epiduo
• Claravis
• Aczone
• Differin
• Abscorical/Epirus
• Ziana
• Doryx

• Analysis of the Dermatitis drugs market. Revenue forecasts to 2030 are provided for the following drugs:
• Bepanthen/Bepanthol
• Protopic
• Dermovate
• Elocon

• This report provides individual revenue forecasts to 2030 for these regional and national markets:
• North America: US & Canada
• Europe: Germany, France, UK, Italy, Spain, Rest of Europe
• Asia-Pacific: China, Japan, India, Rest of Asia-Pacific
• Latin America: Brazil, Mexico, Rest of Latin America
• Middle East & Africa (MEA): Saudi Arabia, South Africa, Rest of MEA

Each regional market is further segmented by indication: psoriasis, skin infection, acne, dermatitis and others.

• This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.

• Our study includes SWOT analysis and Porter’s Five Force analysis of the dermatological drugs market.

• Our study discusses the selected leading companies that are the major players in the dermatological drugs market:
• AbbVie
• Allergan
• Amgen
• Bausch Health
• Bayer AG
• Bristol-Myers Squibb
• Celgene Corporation
• Eli Lilly
• Galderma (Nestle Skin Health S.A.)
• GlaxoSmithKline (GSK)
• Johnson & Johnson
• LEO Pharma
• Merck & Co, Inc.
• Novartis
• Pfizer

• Key questions answered by this report:
• How is the dermatological drugs market evolving?
• What is driving and restraining the dermatological drugs market?
• What are the market shares of each segment of the overall dermatological drugs market in 2019?
• How will each dermatological drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030?
• How will the market shares for each dermatological drugs submarket develop from 2020 to 2030?
• Which individual therapies will prevail and how will these shifts be responded to?
• What will be the main driver for the overall market from 2020 to 2030?
• How will political and regulatory factors influence the regional markets and submarkets?
• Will leading national dermatological drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve during the period between 2019 and 2030?
• Visiongain understands that the dermatological drugs market will register strong growth. This report examines in detail the market by region, by submarket, and as a whole, and provides the reader with a thorough overview of the market to identify key growth areas and business opportunities to exploit. This is where Visiongain adds value.

Visiongain’s study is intended for anyone requiring commercial analyses for the dermatological drugs market. You find data, trends and predictions.

Buy our report today Dermatological Drugs Market Forecast 2020-2030: Psoriasis, Skin Infection, Acne, Dermatitis, Others.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help:

Download sample pages

Complete the form below to download your free sample pages for Dermatological Drugs Market Forecast 2020-2030

Download sample pages

Complete the form below to download your free sample pages for Dermatological Drugs Market Forecast 2020-2030

Latest Pharma news

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021


Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021


Visiongain Publishes Aptamer Technologies Market Report 2021-2031

Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.

29 April 2021


Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.

29 April 2021